Every material Form 8-K Camp4 Therapeutics Corp has filed with the SEC since August 04, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
At an Analyst Day on September 28, 2026, CAMP4 Therapeutics described the design and timing of its planned Phase 1/2 ASCEND trial of CMP-002 in SYNGAP1-related disorder and gave a pipeline update. The company expects to dose the first patient by the end of 2026 and targets topline data in the first half of 2028, so the update sets out timelines but reports no clinical results or financial figures.
The company expects to dose the first patient in the ASCEND trial by the end of 2026 and targets topline data in the first half of 2028.
The trial plans three multiple ascending dose cohorts with a minimum of eight participants each, randomized 3:1 to intrathecal CMP-002 or a sham procedure.
The company expects to designate a development candidate in its SHANK3 program for Phelan-McDermid Syndrome in 2027, citing more than 45,000 US patients.
CAMP4 Therapeutics reported a second-quarter 2026 net loss of $33.5 million, up from $12.6 million a year earlier, mainly due to a $20.9 million non-cash loss from a change in fair value of a derivative tranche liability tied to its September 2025 private placement. Revenue rose to $1.8 million from $1.5 million, and the company said its cash is sufficient to fund planned activities through the end of 2028.
Net loss for the quarter ended June 30, 2026, was $33.5 million, compared with $12.6 million a year earlier.
Research and collaboration revenue was $1.8 million, up from $1.5 million; R&D expenses were $10.8 million and G&A expenses were $4.3 million.
Cash and cash equivalents were $86.4 million at June 30, 2026, down from $109.5 million at December 31, 2025; the company closed a second private placement tranche raising $50.1 million after quarter-end.
Regulatory clearance was received in Australia and Argentina for a Phase 1/2 trial of CMP-002, with trial launch expected in Q4 2026.
On August 3, 2026, CAMP4 Therapeutics completed the second closing of its private placement, selling common shares and pre-funded warrants for approximately $50.1 million in gross proceeds before placement agent fees and other expenses. The closing followed Australian clearance to start a Phase 1/2 trial of CMP-002 and a Price Threshold Waiver under the original agreement. The new shares and warrants add to the company's share count, and the company says the proceeds will support CMP-002 and its early-stage pipeline.
Second closing on August 3, 2026 issued 10,756,498 shares at $1.53 and 21,925,368 pre-funded warrants at $1.5299 each.
Gross proceeds of approximately $50.1 million, before placement agent fees and other expenses.
Also sold 39,306 shares at $1.65 to certain management, directors and co-founders.
Closing was triggered after July 2026 clearance for the CMP-002 Phase 1/2 trial in Australia; securities are unregistered and subject to a Registration Rights Agreement dated September 9, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Camp4 Therapeutics Corp filing is on SEC EDGAR ↗. 8-K briefs of other companies →